ClinicalTrials.gg
CompletedNCT04724837ZENITH-CKDUpdated Jul 30, 2024Results posted

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

A Phase 2 interventional study of Zibotentan and Dapagliflozin in Chronic Kidney Disease, sponsored by AstraZeneca. Completed at 164 sites in 19 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-07-30.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
542
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Renal Insufficiency, Chronic by AstraZeneca — 6 open to participants now, 11 under way, 5 of them phase 3. Renal Insufficiency, Chronic · AstraZeneca.

Enrollment
13th of 38
542 · median 170
Started
2021
with 7 others
Phase 2
9 of 54
none open now
Registered
18th of 54
by date

Among the 54 studies in Renal Insufficiency, Chronic by AstraZeneca, this one is the 13th largest by enrollment of the 38 interventional ones that give a count, is one of 8 that started in 2021, is one of 9 in phase 2, and was the 18th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 54 studies in Renal Insufficiency, Chronic by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Renal Insufficiency, Chronic by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and dapagliflozin 10 mg as monotherapy in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) ≥ 20 mL/min/1.73 m\^2, and urinary albumin to creatinine ratio (UACR) ≥ 150 mg/g and ≤ 5000 mg/g.

Read the detailed description

The study will be conducted in approximately 220 sites in North America, South America, Africa, Asia/Pacific, and European countries.

Participants will be randomized to 12 weeks of treatment plus 2 weeks follow-up.

After screening, eligible participants will be stratified by diabetes (diabetic kidney disease [DKD] versus non-diabetes mellitus [non-DM] CKD) and baseline eGFR (below or equal versus above 45 mL/min/1.73m\^2).

A total of 495 participants will be randomised into this study, including participants randomised under the earlier study design. Four hundred and fifteen (415) participants will be randomised to have 166 participants in zibotentan Dose A/dapagliflozin 10 mg combination arm and dapagliflozin 10 mg monotherapy arm, and 83 participants in the zibotentan Dose B/dapagliflozin 10 mg combination arm.

  • Zibotentan Dose A + Dapagliflozin 10 mg once daily.
  • Zibotentan Dose B + Dapagliflozin 10 mg once daily.
  • Placebo + Dapagliflozin 10 mg once daily

Participants who were previously randomised cannot be re-randomised.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • Zibotentan
  • Nephrology
  • Dapagliflozin
  • Sodium-glucose co-transporter 2
  • sodium-glucose co-transporter 2 inhibitor
  • Kidney diseases
  • Endothelin antagonist
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Diagnosis of Chronic kidney disease (CKD), defined as:

    (a) chronic kidney disease epidemiology collaboration (CKD-EPI) ≥ 20 mL/min/1.73 m\^2, and (b) UACR ≥ 150 and ≤ 5000 mg albumin/g creatinine, based on a single first morning void spot urine sample at screening.

  • No current or prior (within 1 month of screening) medical treatment with an SGLT2i (sodium-glucose co-transporter 2 inhibitor) or any fixed dose combination with SGLT2i.
  • If Angiotensin-converting enzyme inhibitors (ACEi) and/or Angiotensin receptor blockers (ARB) and/or mineralocorticoid receptor agonist are prescribed, the dose must be stable ≥ 4 weeks before screening. Participants who have been deemed unable to tolerate ACEi or ARB therapy due to allergy or complications can be enrolled.
  • No current or prior treatment within 6 months prior to screening with cytotoxic therapy, therapy or other immunotherapy for primary or secondary kidney disease.
  • ≤ 40 kg/m\^2.
  • Male or female of non-.
  • Female participants must have a negative pregnancy test at screening, must not be lactating, and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:

    • defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone and luteinizing hormone levels in the postmenopausal range.
    • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation.
  • Male participants must be surgically sterile, abstinent, or in conjunction with a female sexual partner, using a highly effective method of for the duration of the study (from the time they sign consent) and for 3 months after the last dose of product to prevent any pregnancies. Male study participants must not donate or bank sperm during this same time period.
  • Capable of giving signed , as described in Appendix A, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Provision of signed and dated, written ICF prior to any mandatory study-specific procedures, sampling, and analyses.
  • Provision of signed and dated written Genetic informed consent prior to collection of samples (optional) for genetic analysis.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Minimal change disease, unstable rapidly progressing renal disease, and/or renal disease requiring significant , autosomal dominant or autosomal recessive polycystic kidney disease.
  • Participants with classification functional heart failure (HF) class III or IV.
  • Acute coronary syndrome events within 3 months prior to screening.
  • Participants with a B-type natriuretic peptide (BNP) ≥ 200 pg/mL or NT-proBNP ≥ 600 pg/mL (BNP ≥ 400 pg/mL or NT-proBNP ≥ 1200 pg/mL, respectively, if associated with atrial fibrillation) measured by local laboratory at screening (Visit 1).
  • Participants with unstable HF requiring hospitalisation for optimisation of HF treatment and/or who have not been stable on HF therapy within 6 months prior to screening
  • Heart failure due to cardiomyopathies that would primarily require other specific treatment: eg, cardiomyopathy due to pericardial disease, amyloidosis or other infiltrative diseases, cardiomyopathy related to congenital heart disease, primary hypertrophic cardiomyopathy, cardiomyopathy related to toxic or infective conditions (ie, chemotherapy, infective myocarditis, septic cardiomyopathy).
  • High output HF (eg, due to hyperthyroidism or Paget's disease).
  • Heart failure due to primary cardiac valvular disease/ dysfunction, severe functional mitral or tricuspid valve insufficiency, or planned cardiac valve repair/replacement.
  • Participants with uncontrolled diabetes mellitus ( > 12%).
  • Participants with Type 1 diabetes mellitus.
  • Hyponatremia, defined as serum Na+ \< 135 mmol/L at the time of screening (Visit 1).
  • Intermittent or persistent second or third degree atrioventricular block after sinus node dysfunction, with bradycardia or sinus pause when not treated with pacemaker.
  • Prolonged (QTcF > 470 ms) on at screening (Visit 1) or randomisation visit (Visit 2), known congenital long QT syndrome or history of QT prolongation associated with other medications.
  • History of any life-threatening cardiac dysrhythmia (continuous or paroxysmal or uncontrolled ventricular rate in participants with atrial fibrillation or atrial flutter).
  • Cardiac surgery or non-elective percutaneous coronary interventions (PCI/TAVI) (within 3 months) or open chest coronary artery bypass grafting or valvular repair/replacement (within 3 months) prior to screening or is planned to undergo any of these procedures after randomisation.
  • Heart transplantation or left ventricular assist device at any time.
  • Kidney or any organ transplantation.
  • History or ongoing allergy/, as judged by the investigator, to SGLT2i (eg, dapagliflozin, canagliflozin, empagliflozin) or drugs with a similar chemical structure to zibotentan.
  • Any clinically significant disease or disorder (eg, cardiovascular, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, psychiatric, major physical impairment), which might put the participant at risk because of participation in the study, or probable alternative primary reason for participant's symptoms in judgment of investigator, including but not limited to:

    • Isolated pulmonary arterial hypertension [PAP] (defined as mean PAP ≥ 25 mmHg at rest) or right ventricular failure; in the absence of left-sided HF
    • Anaemia defined as (Hb) level \< 100 g/L or 10 g/dL at screening (Visit 1)
    • Severe or other lung disease including but not limited to pulmonary fibrosis requiring chronic oxygen therapy, regular nebuliser use, or oral therapy
  • Stroke, , carotid surgery, or carotid angioplasty within previous 3 months prior to screening.
  • Severe hepatic impairment ( class C Hepatic impairment), or alanine transaminase > 2x the [ULN]; or total > 2x ULN at time of screening.
  • Participants with newly detected pathological laboratory values or an ongoing disease condition requiring investigation and/or initiation or adjustment of current treatment (in the opinion of the investigator).
  • Positive antibody, or virus, surface antigen at screening.
  • Positive (HIV) test.
  • Participants treated with strong or moderate inhibitor or inducer.
  • Any condition outside the renal and CV disease area, such as but not limited to , with a of less than 2 years based on investigator's clinical judgment.
  • Confirmation of corona virus disease- 2019 (COVID-19) infection:

    • Participant has a positive test result for severe acute respiratory syndrome coronavirus 2 during screening. Participants who are not hospitalised for COVID-19 infections can be re screened 4 weeks after they have recovered.
    • Participant has been previously hospitalised with COVID-19 infection.
  • \< 50% measured by echocardiogram at screening.
  • Participation in another clinical study with an product administered in the last 3 months prior to screening.
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  • Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  • Previous randomisation into the present study.
  • Plasma donation within 1 month of the visit at the clinic or any blood donation/blood loss > 500 mL during the 3 months prior to any visit at the clinic.
  • Male participant in a sexually active relation with pregnant or breastfeeding partner.
  • Participants can decline to participate in the genetic research and may still participate in the study. Exclusion from this optional genetic research may be for any of the exclusion criteria specified for the main study or any of the following:

    • Previous bone marrow transplant.
    • Non-leukocyte depleted whole blood transfusion within 120 days of genetic sample collection.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
542 participants (actual)

Study arms

  • Experimental
    Zibotentan Dose A + Dapagliflozin

    Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.

    Drug: Zibotentan · Drug: Dapagliflozin

  • Experimental
    Zibotentan Dose B + Dapagliflozin

    Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.

    Drug: Zibotentan · Drug: Dapagliflozin

  • Experimental
    Placebo + Dapagliflozin

    Participants will receive once daily oral dose of dapagliflozin 10 mg and placebo for 12 weeks.

    Drug: Dapagliflozin · Drug: Placebo

Interventions

  • Participants will receive zibotentan as per the arms they are randomized.

  • Participants will receive 10 mg dapagliflozin as per the arms they are randomized.

  • DrugPlacebo

    Participants will receive placebo as per the arms they are randomized to.

06

What researchers measure

Primary outcomes

  1. Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12

    The effect of zibotentan 1.5/dapagliflozin 10 mg versus dapagliflozin 10 mg on UACR was assessed.

    Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)

Secondary outcomes

  1. Change in UACR From Baseline to Week 12

    The effect of zibotentan 0.25 mg/dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy on UACR was assessed.

    Time frame: From baseline (Week 0 [Day 1]) until Week 12

  2. Change in Office Systolic Blood Pressure From Baseline to Week 12

    The change in office systolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.

    Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)

  3. Change in Office Diastolic Blood Pressure From Baseline to Week 12

    The change in office diastolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.

    Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)

  4. Change in UACR From Baseline to Week 12

    The assessment of dose-response and relationship across different dose of zibotentan/dapagliflozin and dapagliflozin alone on UACR reduction.

    Time frame: From baseline (Week 0 [Day 1]) until Week 12 (Day 84)

  5. Change in eGFR From Baseline to Week 1, Week 12, and Week 14

    The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.

    Time frame: From baseline (Week 0 [Day 1]) until Week 1 (Day 8), Week 12 (Day 84), and Week 14 (Day 98)

  6. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

    The safety and tolerability of all doses of zibotentan combined with dapagliflozin 10 mg and dapagliflozin 10 mg monotherapy was assessed.

    Time frame: From Screening (Day -28) until Follow-up visit (Day 98), up to 126 days

  7. Change in eGFR From Week 1 to Week 12

    The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.

    Time frame: From Week 1 (Day 8) to Week 12 (Day 84)

07

Results

Posted Jul 30, 2024
Limitations and caveats
No multiple testing correction was considered in this early phase study.

Participant flow

The study was conducted in approximately 170 sites in North America, South America, Africa, Asia/Pacific, and European countries.

Participant flow — Overall Study
MilestoneZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Started91179177
Full analysis set91179177
Safety analysis set91179177
Completed82142157
Not completed93720
Withdrew: Other4160
Withdrew: Withdrawal by subject299
Withdrew: Adverse event274
Withdrew: Lost to follow-up013
Withdrew: Physician decision120
Withdrew: Death001
Withdrew: Failure to meet randomization criteria013
Withdrew: Study terminated by sponsor010

Outcome measures

PrimaryChange in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12

The effect of zibotentan 1.5/dapagliflozin 10 mg versus dapagliflozin 10 mg on UACR was assessed.

Time frame:
From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Reported as:
Geometric mean · milligram/gram (mg/g)
Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 12
milligram/gram (mg/g)Zibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Change in Urinary Albumin to Creatinine Ratio (UACR) From Baseline to Week 120.48 ± 1.0940.72 ± 1.090
Statistical analysis
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · p = <0.001 · Adjusted % mean change from baseline: -33.7 · 90% CI -42.5 to -23.5If adjusted percentage mean change from baseline \>0 then the result favours Dapa 10 mg + PBO for UACR.
SecondaryChange in UACR From Baseline to Week 12

The effect of zibotentan 0.25 mg/dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy on UACR was assessed.

Time frame:
From baseline (Week 0 [Day 1]) until Week 12
Reported as:
Geometric mean · mg/g
Change in UACR From Baseline to Week 12
mg/gZibotentan 0.25 mg + DapagliflozinPlacebo + Dapagliflozin
Change in UACR From Baseline to Week 120.52 ± 1.1060.72 ± 1.090
Statistical analysis
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · p = 0.002 · Adjusted % mean change from baseline: -27.0 · 90% CI -38.4 to -13.6If adjusted percentage mean change from baseline \>0 then the result favours Dapa 10 mg + PBO for UACR.
SecondaryChange in Office Systolic Blood Pressure From Baseline to Week 12

The change in office systolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.

Time frame:
From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Office Systolic Blood Pressure From Baseline to Week 12
Millimeters of mercury (mmHg)Zibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Change in Office Systolic Blood Pressure From Baseline to Week 12-7.1 (-10.0 to -4.1)-11.0 (-13.5 to -8.4)-3.4 (-5.8 to -1.0)
Statistical analysis
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Least square (ls) mean cfb: -3.6 · 90% CI -6.8 to -0.5If mean change from baseline (CFB) \>0 then the result favours Dapa 10 mg + PBO for office systolic blood pressure.
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: -7.6 · 90% CI -10.3 to -4.9If mean change from baseline \>0 then the result favours Dapa 10 mg + PBO for office systolic blood pressure.
SecondaryChange in Office Diastolic Blood Pressure From Baseline to Week 12

The change in office diastolic blood pressure for doses of zibotentan combined with dapagliflozin 10 mg versus dapagliflozin 10 mg monotherapy was assessed.

Time frame:
From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Reported as:
Mean · mmHg
Change in Office Diastolic Blood Pressure From Baseline to Week 12
mmHgZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Change in Office Diastolic Blood Pressure From Baseline to Week 12-4.3 (-6.2 to -2.5)-6.8 (-8.4 to -5.2)-1.4 (-2.9 to 0.1)
Statistical analysis
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: -3.0 · 90% CI -5.0 to -1.0If mean change from baseline \>0 then the result favours Dapa 10 mg + PBO for office diastolic blood pressure.
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: -5.4 · 90% CI -7.1 to -3.7If mean change from baseline \>0 then the result favours Dapa 10 mg + PBO for office diastolic blood pressure.
SecondaryChange in UACR From Baseline to Week 12

The assessment of dose-response and relationship across different dose of zibotentan/dapagliflozin and dapagliflozin alone on UACR reduction.

Time frame:
From baseline (Week 0 [Day 1]) until Week 12 (Day 84)
Reported as:
Geometric mean · mg/g
Change in UACR From Baseline to Week 12
mg/gZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Change in UACR From Baseline to Week 120.52 ± 1.1060.48 ± 1.0940.72 ± 1.090
Statistical analysis
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Adjusted % mean change from baseline: -27.0 · 90% CI -38.4 to -13.6If adjusted percentage mean change from baseline \>0 then the result favours Dapa 10 mg + PBO for UACR.
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Adjusted % mean change from baseline: -33.7 · 90% CI -42.5 to -23.5If adjusted percentage mean change from baseline \>0 then the result favours Dapa 10 mg + PBO for UACR.
SecondaryChange in eGFR From Baseline to Week 1, Week 12, and Week 14

The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.

Time frame:
From baseline (Week 0 [Day 1]) until Week 1 (Day 8), Week 12 (Day 84), and Week 14 (Day 98)
Reported as:
Mean · milliliters/minutes/1.73 square metres
Change in eGFR From Baseline to Week 1, Week 12, and Week 14
milliliters/minutes/1.73 square metresZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Week 1-2.0 (-3.5 to -0.5)-3.9 (-5.2 to -2.6)-3.1 (-4.4 to -1.8)
Week 12-3.1 (-4.7 to -1.5)-3.0 (-4.4 to -1.6)-1.9 (-3.3 to -0.6)
Week 140.2 (-1.4 to 1.8)-2.0 (-3.4 to -0.6)0.1 (-1.2 to 1.5)
Statistical analysis
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: 1.1 · 90% CI -0.5 to 2.6If mean change from baseline \<0 then the result favours Dapa 10 mg + PBO for eGFR.
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: -0.8 · 90% CI -2.1 to 0.5If mean change from baseline \<0 then the result favours Dapa 10 mg + PBO for eGFR.
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: -1.2 · 90% CI -2.8 to 0.5If mean change from baseline \<0 then the result favours Dapa 10 mg + PBO for eGFR.
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: -1.1 · 90% CI -2.5 to 0.3If mean change from baseline \<0 then the result favours Dapa 10 mg + PBO for eGFR.
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: 0.1 · 90% CI -1.6 to 1.8If mean change from baseline \<0 then the result favours Dapa 10 mg + PBO for eGFR.
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean cfb: -2.1 · 90% CI -3.5 to -0.7If mean change from baseline \<0 then the result favours Dapa 10 mg + PBO for eGFR.
SecondaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)

The safety and tolerability of all doses of zibotentan combined with dapagliflozin 10 mg and dapagliflozin 10 mg monotherapy was assessed.

Time frame:
From Screening (Day -28) until Follow-up visit (Day 98), up to 126 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
ParticipantsZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Any AE458666
AE with outcome of death001
Any SAE2104
Any AE leading to discontinuation of investigational product (IP)11227
Any AE leading to dose interruption3710
Any AE leading to withdrawal from study274
Any AE possibly related to IP143316
SecondaryChange in eGFR From Week 1 to Week 12

The effect of different doses of zibotentan and dapagliflozin 10 mg in combination versus dapagliflozin 10 mg monotherapy on eGFR was assessed.

Time frame:
From Week 1 (Day 8) to Week 12 (Day 84)
Reported as:
Mean · milliliters/minutes/1.73 square metres
Change in eGFR From Week 1 to Week 12
milliliters/minutes/1.73 square metresZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Change in eGFR From Week 1 to Week 12-1.1 (-2.5 to 0.4)0.9 (-0.2 to 2.0)1.2 (0.1 to 2.2)
Statistical analysis
  • Zibotentan 0.25 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean change: -2.2 · 90% CI -4.0 to -0.4If mean change \<0 then the result favours Dapa 10 mg + PBO for eGFR.
  • Zibotentan 1.5 mg + Dapagliflozin vs Placebo + Dapagliflozin · Mixed Models Analysis · Ls mean change: -0.3 · 90% CI -1.8 to 1.3If mean change \<0 then the result favours Dapa 10 mg + PBO for eGFR.

Adverse events

Collected over From screening (Day -28) to Final Follow-up (Day 98), up to 126 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zibotentan 0.25 mg + Dapagliflozin0/91 (0%)2/91 (2.2%)14/91 (15.4%)
Zibotentan 1.5 mg + Dapagliflozin0/179 (0%)10/179 (5.6%)24/179 (13.4%)
Placebo + Dapagliflozin1/177 (0.6%)4/177 (2.3%)6/177 (3.4%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
Cardiac failure congestiveCardiac disorders1/910/1790/177
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/910/1790/177
GastroenteritisInfections and infestations0/910/1791/177
RestlessnessPsychiatric disorders0/910/1791/177
Acute kidney injuryRenal and urinary disorders0/911/1791/177
Sudden cardiac deathGeneral disorders0/910/1791/177
Cerebrovascular accidentNervous system disorders0/911/1790/177
Acute myocardial infarctionCardiac disorders0/911/1790/177
Cardiac failureCardiac disorders0/911/1790/177
Chronic left ventricular failureCardiac disorders0/911/1790/177
Most frequent other events
Most frequent other events
EventZibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + Dapagliflozin
HeadacheNervous system disorders6/918/1792/177
Metabolic acidosisMetabolism and nutrition disorders5/917/1792/177
HypertensionVascular disorders5/910/1791/177
Brain natriuretic peptide increasedInvestigations2/919/1791/177

Baseline characteristics

The full analysis set included all participants who were randomised and received any study intervention.

Age, Continuous
Age, Continuous(Years)Zibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + DapagliflozinTotal
Mean61.3 ± 12.7262.7 ± 12.3363.6 ± 11.6062.8 ± 12.13
Sex: Female, Male
Sex: Female, Male(Participants)Zibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + DapagliflozinTotal
Female285555138
Male63124122309
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + DapagliflozinTotal
Hispanic or Latino235846127
Not Hispanic or Latino68121131320
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zibotentan 0.25 mg + DapagliflozinZibotentan 1.5 mg + DapagliflozinPlacebo + DapagliflozinTotal
American Indian or Alaska Native0000
Asian18262670
Native Hawaiian or Other Pacific Islander0202
Black or African American7172246
White56124125305
More than one race0000
Unknown or Not Reported1010424
08

Study locations

164 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Downey, California 90242, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Ontario, California 91762, United States
  • Research Site
    S. Gate, California 90280, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Vacaville, California 95687, United States
  • Research Site
    Fort Lauderdale, Florida 33308, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    New Port Richey, Florida 34652, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Riverview, Florida 33578, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Augusta, Georgia 30904, United States
  • Research Site
    Fayetteville, Georgia 30214, United States
  • Research Site
    Wichita, Kansas 67214-2943, United States
  • Research Site
    Owensboro, Kentucky 42303, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Flint, Michigan 48532, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Jacksonville, North Carolina 28546, United States
  • Research Site
    Kinston, North Carolina 28504, United States
  • Research Site
    Morehead City, North Carolina 28557, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Marion, Ohio 43302, United States
  • Research Site
    Chester, Pennsylvania 19013, United States
  • Research Site
    Memphis, Tennessee 38104, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Arlington, Texas 76002, United States
  • Research Site
    Conroe, Texas 77384, United States
  • Research Site
    Corpus Christi, Texas 78414, United States
  • Research Site
    El Paso, Texas 79935, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Odessa, Texas 79761, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    Waxahachie, Texas 75165, United States
  • Research Site
    Forest, Virginia 24551, United States
  • Research Site
    Newport News, Virginia 23606, United States
  • Research Site
    Spokane, Washington 99204, United States
  • Research Site
    Buenos Aires, C1425AGC, Argentina
  • Research Site
    Caba, C1120AAC, Argentina
  • Research Site
    Caba, C1440AAD, Argentina
  • Research Site
    Cordoba, 5003, Argentina
  • Research Site
    Corrientes, W3400AMZ, Argentina
  • Research Site
    Junín, 6000, Argentina
  • Research Site
    Mar del Plata, B7600FZN, Argentina
  • Research Site
    Mar del Plata, B7600, Argentina
  • Research Site
    San Luis, 5700, Argentina
  • Research Site
    San Miguel de Tucuman, 4000, Argentina
  • Research Site
    Santa Fe, S3000, Argentina
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Birtinya, 4575, Australia
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Gosford, 2250, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Botucatu, 18618-687, Brazil
  • Research Site
    Campinas, 13010-001, Brazil
  • Research Site
    Curitiba, 80440-020, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Santo Andre, 09090-790, Brazil
  • Research Site
    Sao Paulo, 04039-000, Brazil
  • Research Site
    Sao Paulo, 5403-000, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01228-200, Brazil
  • Research Site
    Gabrovo, 5300, Bulgaria
  • Research Site
    Kozloduy, 3320, Bulgaria
  • Research Site
    Montana, 3400, Bulgaria
  • Research Site
    Plovdiv, 4023, Bulgaria
  • Research Site
    Sliven, 8800, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1510, Bulgaria
  • Research Site
    Stara Zagora, 6000, Bulgaria
  • Research Site
    St. John's, Newfoundland and Labrador A1A 3R5, Canada
  • Research Site
    London, Ontario N6A-5A5, Canada
  • Research Site
    Toronto, Ontario M5N 1C1, Canada
  • Research Site
    Waterloo, Ontario N2T 0C1, Canada
  • Research Site
    Pula, 52000, Croatia
  • Research Site
    Vinkovci, 32100, Croatia
  • Research Site
    Gentofte, 2820, Denmark
  • Research Site
    Roskilde, 4000, Denmark
  • Research Site
    Århus N, 8200, Denmark
  • Research Site
    Batumi, 6010, Georgia
  • Research Site
    Gori, 1400, Georgia
  • Research Site
    Gurjaani, 1500, Georgia
  • Research Site
    Kutaisi, 4600, Georgia
  • Research Site
    Marneuli, 3000, Georgia
  • Research Site
    Tbilisi, 0102, Georgia
  • Research Site
    Tbilisi, 0114, Georgia
  • Research Site
    Tbilisi, 0144, Georgia

Showing the first 100 of 164 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Smeijer JD, Kohan DE, Webb DJ, Dhaun N, Heerspink HJL. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. Curr Opin Nephrol Hypertens. 2021 Jul 1;30(4):456-465. doi: 10.1097/MNH.0000000000000716. PubMed 33990507 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jun 2023, 25 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 25 months is above that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 26, 2021
StartActual
Apr 28, 2021
Primary completionActual
Jun 1, 2023
CompletionActual
Jun 1, 2023
Results first posted
Jul 30, 2024
Last update
Jul 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04724837
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 26, 2021
Start date
Apr 28, 2021
Primary completion
Jun 1, 2023
Completion
Jun 1, 2023
Results posted
Jul 30, 2024
Last update
Jul 30, 2024

Study contacts

David C Wheeler, MB ChB, MD, FRCP
principal investigator · Centre for Nephrology Royal Free Campus University College London Rowland Hill Street London NW3 2PF United Kingdom
Jamie P. Dwyer, M.D.
principal investigator · Nephrology Clinical Trials Center Nephrology and Hypertension Vanderbilt University Medical Center Nashville TN United States of America

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion